THE DMT LIBRARY · RESEARCH TRACKER
DMT clinical trials, worldwide.
Every study on ClinicalTrials.gov that gives participants DMT, ayahuasca or 5-MeO-DMT. ClinicalTrials.gov is the public registry run by the US National Library of Medicine, where research teams around the world describe their studies before and while they run them. This list refreshes from the registry every day.
This is a list of research studies, for education. It is not medical advice and not a guide to treatment. Shroomverse has no connection to any study listed and doesn’t recommend taking part in any of them. A registered study is a plan: being listed here says nothing about whether DMT, ayahuasca or 5-MeO-DMT works or is safe. For what the published trials have found so far, see DMT therapy: what the clinical trials have tested.
55 registered studies
12 recruiting now
1 not yet recruiting
12 countries with a site
Registry data checked 2 November 2026. Source: ClinicalTrials.gov.
All trials
Showing 55 of 55 trials
Acute Effects of Intravenous 5-MeO-DMT in Healthy Participants
- Conditions
- 5-methoxy-dimethyltryptamine (5-MeO-DMT)
- Sites
- Switzerland: Basel
- Lead sponsor
- University Hospital, Basel, Switzerland
- Dates
- Start Aug 2026 · main results expected Mar 2027
NCT07444788 on ClinicalTrials.gov · record updated Oct 2026
Inhaled DMT for Major Depressive Disorder
- Conditions
- MDD; Major Depressive Disorder (MDD); Major Depression; Suicidal Ideation; Suicide
- Sites
- Brazil: Fortaleza, Salvador, Rio de Janeiro, Natal, São Paulo
- Lead sponsor
- Universidade Federal do Rio Grande do Norte
- Dates
- Start Aug 2026 · main results expected Feb 2027
NCT07562191 on ClinicalTrials.gov · record updated Jul 2026
Effects of a Sigle Dose of Ayahuasca in Patients With Psychogenic Non-epileptic Seizures: an Open Label Clinical Trial
- Conditions
- Non Epileptic Seizures
- Sites
- Brazil: Ribeirão Preto
- Lead sponsor
- University of Sao Paulo
- Dates
- Start Jul 2026 · main results expected Aug 2027
NCT07747324 on ClinicalTrials.gov · record updated Aug 2026
Ayahuasca, Esketamine and Premenstrual Symptoms
- Conditions
- Healthy Women Volunteers
- Sites
- Brazil: Ribeirão Preto
- Lead sponsor
- University of Sao Paulo
- Dates
- Start Dec 2025 · main results expected Jun 2026
NCT07317232 on ClinicalTrials.gov · record updated Jan 2026
Ayahuasca, Esketamine and Body Image Perception
- Conditions
- Healthy Women Volunteers
- Sites
- Brazil: Ribeirão Preto
- Lead sponsor
- University of Sao Paulo
- Dates
- Start Dec 2025 · main results expected Jun 2026
NCT07317219 on ClinicalTrials.gov · record updated Jan 2026
Ayahuasca, Esketamine and PTSD
- Conditions
- Posttraumatic Stress Disorder (PTSD)
- Sites
- Brazil: Ribeirão Preto
- Lead sponsor
- University of Sao Paulo
- Dates
- Start Dec 2025 · main results expected Jun 2026
NCT07317206 on ClinicalTrials.gov · record updated Jan 2026
Antidepressant Response of DMT Masked With Propofol
- Conditions
- Major Depressive Disorder; Psychedelic Experiences
- Sites
- Switzerland: Basel
- Lead sponsor
- University Hospital, Basel, Switzerland
- Dates
- Start Aug 2025 · main results expected Mar 2029
NCT06927076 on ClinicalTrials.gov · record updated Apr 2026
The Potential Therapeutic Effects of Psychedelic, N, N-dimethyltryptamine (DMT), on Alcohol Use Disorder (AUD)
- Conditions
- Alcohol Use Disorder (AUD); Alcohol-Related Disorders; Alcohol Use
- Sites
- United States: New Haven
- Lead sponsor
- Yale University
- Dates
- Start Aug 2025 · main results expected Aug 2027
NCT06070649 on ClinicalTrials.gov · record updated Sep 2026
Direct Comparison of Altered States of Consciousness Induced by LSD, Psilocybin, and DMT in Healthy Participants
- Conditions
- Healthy
- Sites
- Switzerland: Basel
- Lead sponsor
- University Hospital, Basel, Switzerland
- Dates
- Start Apr 2025 · main results expected Aug 2026
NCT06899334 on ClinicalTrials.gov · record updated Mar 2025
Study of the Safety, Tolerability, Electrophysiological Effects and Efficacy of DMT in Humans
- Conditions
- Major Depression Disorder; Depression
- Sites
- United States: West Haven
- Lead sponsor
- Deepak C. D'Souza
- Dates
- Start Mar 2025 · main results expected Dec 2027
NCT06671977 on ClinicalTrials.gov · record updated Jun 2026
Investigation of Psychedelic Effects in Psychoactive Substances
- Conditions
- Psychedelic Effects in Healthy Volunteers
- Sites
- United States: Baltimore
- Lead sponsor
- Johns Hopkins University
- Dates
- Start Feb 2025 · main results expected Jun 2027
NCT06772753 on ClinicalTrials.gov · record updated Feb 2026
An Open-Label Study to Evaluate the Safety, Tolerability and Pharmacodynamics of BPL-003 in Patients With Treatment Resistant Depression
- Conditions
- Treatment Resistant Depression
- Sites
- United Kingdom: Liverpool, London
- Lead sponsor
- Beckley Psytech Limited
- Dates
- Start Feb 2023 · main results expected Nov 2026
NCT05660642 on ClinicalTrials.gov · record updated Jul 2026
Neural Effects of Intravenous N,N-dimethyltryptamine (DMT)
- Conditions
- Healthy Participants Study
- Sites
- United States: La Jolla
- Lead sponsor
- Jon Dean
- Dates
- Start Sep 2026 · main results expected Sep 2028
NCT07693257 on ClinicalTrials.gov · record updated Jul 2026
Acute Effects of a Single Dose of Ayahuasca on Cerebral Metabolism in Healthy Volunteers: a PET Study
- Conditions
- Healthy Adult Participants
- Sites
- Brazil: Ribeirão Preto
- Lead sponsor
- University of Sao Paulo
- Dates
- Start Oct 2026 · main results expected Dec 2027
NCT07893912 on ClinicalTrials.gov · record updated Oct 2026
Single and Repeat Doses of DMT in Healthy Subjects
- Conditions
- Stroke
- Sites
- Netherlands: Leiden
- Lead sponsor
- Algernon Pharmaceuticals
- Dates
- Start Jan 2023 · main results expected Mar 2026
NCT05559931 on ClinicalTrials.gov · record updated Jan 2025
Trifecta Research Study
- Conditions
- PTSD - Post Traumatic Stress Disorder; Cognitive Dysfunction; Brain Injury; Depression - Major Depressive Disorder; Suicidal Ideation
- Sites
- United States: Northridge
- Lead sponsor
- Axial Therapeutic Research
- Dates
- Start Aug 2022 · main results expected Feb 2026
NCT07717866 on ClinicalTrials.gov · record updated Jul 2026
Fixed Order, Open-Label, Dose-Escalation Study of DMT in Humans
- Conditions
- Major Depressive Disorder; Depression
- Sites
- United States: West Haven
- Lead sponsor
- Yale University
- Dates
- Start Mar 2021 · main results expected Jul 2026
NCT04711915 on ClinicalTrials.gov · record updated Aug 2025
Pharmacokinetics and Safety of GH001 Delivered Via a GH001 Aerosol Delivery System in Healthy Subjects
- Conditions
- Healthy Adult
- Sites
- United States: Miami
- Lead sponsor
- GH Research Ireland Limited
- Dates
- Start Mar 2026 · main results expected May 2026
NCT07540494 on ClinicalTrials.gov · record updated Oct 2026
Acute Analgesic Effects of DMT on Experimentally Induced Pain in Healthy Participants
- Conditions
- Healthy
- Sites
- Switzerland: Basel
- Lead sponsor
- University Hospital, Basel, Switzerland
- Dates
- Start Jan 2025 · main results expected Sep 2025
NCT06180759 on ClinicalTrials.gov · record updated Apr 2026
Efficacy of Sublingual 5-MeO-DMT for Reducing Anxiety and Depression in MCI
- Conditions
- Mild Cognitive Impairment; Anxiety State; Depression Anxiety Disorder
- Sites
- Argentina: San Juan
- Lead sponsor
- Biomind Labs Inc.
- Dates
- Start Dec 2024 · main results expected Feb 2025
NCT06812221 on ClinicalTrials.gov · record updated Apr 2025
Safety, Tolerability, and Efficacy of Sublingual Microdoses of 5-MeO-DMT for Depression and Anxiety
- Conditions
- Healthy Volunteers
- Sites
- Argentina: San Juan
- Lead sponsor
- Biomind Labs Inc.
- Dates
- Start Oct 2024 · main results expected Feb 2025
NCT06816667 on ClinicalTrials.gov · record updated Mar 2025
Acute Dose-dependent Effects of DMT-bolus Applications in Healthy Subjects (DMT BDR-Study)
- Conditions
- Healthy
- Sites
- Switzerland: Basel
- Lead sponsor
- University Hospital, Basel, Switzerland
- Dates
- Start Jun 2024 · main results expected Feb 2025
NCT05695495 on ClinicalTrials.gov · record updated Apr 2025
A Study of a N, N-dimethyltryptamine (DMT) Analog (CYB004) in Participants With Generalized Anxiety Disorder (GAD)
- Conditions
- Generalized Anxiety Disorder
- Sites
- United States: Hollywood, Miami Lakes, Atlanta, Decatur, Chicago, Murray
- Lead sponsor
- Cybin IRL Limited
- Dates
- Start May 2024 · main results expected Oct 2025
NCT06051721 on ClinicalTrials.gov · record updated Aug 2026
Molecular Imaging Study of Harmine/DMT: a Basic Research Approach
- Conditions
- Neuropharmacological Investigation of Ayahuasca Constituents DMT and Harmine
- Sites
- Switzerland: Bern, Zurich
- Lead sponsor
- Insel Gruppe AG, University Hospital Bern
- Dates
- Start Jan 2024 · main results expected Feb 2025
NCT06252506 on ClinicalTrials.gov · record updated Mar 2025
Effects of Different Doses of Ayahuasca on Personality in Healthy Volunteers
- Conditions
- Healthy Adult Participants
- Sites
- Brazil: Ribeirão Preto
- Lead sponsor
- University of Sao Paulo
- Dates
- Start Jan 2024 · main results expected Sep 2025
NCT07893769 on ClinicalTrials.gov · record updated Oct 2026
Safety, Tolerability and Antidepressant Effects of DMT in Patients With Depression
- Conditions
- Depressive Disorder; Depression, Unipolar
- Sites
- Brazil: Natal
- Lead sponsor
- Universidade Federal do Rio Grande do Norte
- Dates
- Start Oct 2023 · main results expected Jan 2024
NCT06094907 on ClinicalTrials.gov · record updated May 2024
BPL-003 Efficacy and Safety in Treatment Resistant Depression
- Conditions
- Treatment Resistant Depression
- Sites
- Australia: Sydney, Clayton, Melbourne, Parkville; Germany: Berlin, Frankfurt am Main, Mannheim, Tübingen; Poland: Gdansk, Lodz, Tuszyn, Warsaw; Spain: Barcelona, Madrid, Oviedo, Salamanca; United Kingdom: Exeter, London; United States: Birmingham, Rogers, San Diego, San Francisco, Santa Monica, Fort Collins, Lauderhill, Atlanta, Decatur, Rockville, Boston, Berlin, New York, Portland, DeSoto, Plano, Draper, Madison
- Lead sponsor
- Beckley Psytech Limited
- Dates
- Start Sep 2023 · main results expected Mar 2025
NCT05870540 on ClinicalTrials.gov · record updated Sep 2026
Single-dose Effects of Ayahuasca Compared to Esketamine on Experimentally Induced Pain
- Conditions
- Healthy Adult Participants
- Sites
- Brazil: Ribeirão Preto
- Lead sponsor
- University of Sao Paulo
- Dates
- Start Jun 2023 · main results expected Jul 2025
NCT07910838 on ClinicalTrials.gov · record updated Nov 2026
An Open-Label, Single Dose Study in Patients With Alcohol Use Disorder
- Conditions
- Alcohol Use Disorder
- Sites
- United Kingdom: London
- Lead sponsor
- Beckley Psytech Limited
- Dates
- Start May 2023 · main results expected Oct 2024
NCT05674929 on ClinicalTrials.gov · record updated May 2026
A Trial of GH001 in Patients With Treatment-resistant Depression
- Conditions
- Treatment-resistant Depression
- Sites
- Czechia: Pilsen, Prague; Germany: Dresden, Frankfurt, Münster; Ireland: Dublin, Galway; Netherlands: Maastricht; Poland: Gdansk; Spain: Barcelona, Salamanca
- Lead sponsor
- GH Research Ireland Limited
- Dates
- Start May 2023 · main results expected Oct 2024
NCT05800860 on ClinicalTrials.gov · record updated May 2025
Dose-finding Study for the Combination of DMT and Harmine in Healthy Subjects
- Conditions
- Healthy
- Sites
- Switzerland: Zurich
- Lead sponsor
- Reconnect Labs
- Dates
- Start May 2023 · main results expected Sep 2023
NCT05829603 on ClinicalTrials.gov · record updated Nov 2023
Safety and Tolerability of DMT in Healthy Adults
- Conditions
- Safety Issues; Healthy Volunteers
- Sites
- Brazil: Natal
- Lead sponsor
- Universidade Federal do Rio Grande do Norte
- Dates
- Start Apr 2023 · main results expected Jul 2023
NCT05901012 on ClinicalTrials.gov · record updated Oct 2023
Mindfulness and Psychedelics
- Conditions
- Healthy Participants
- Sites
- Switzerland: Zurich
- Lead sponsor
- Milan Scheidegger
- Dates
- Start Feb 2023 · main results expected Aug 2023
NCT05780216 on ClinicalTrials.gov · record updated Sep 2023
IM and IV SPL026 Drug Product in Healthy Participants
- Conditions
- Major Depressive Disorder
- Sites
- United Kingdom: London
- Lead sponsor
- Small Pharma Ltd
- Dates
- Start Jan 2023 · main results expected Apr 2023
NCT05644093 on ClinicalTrials.gov · record updated Mar 2024
Pharmacokinetics, Safety, and Tolerability of Intramuscular 5-MeO-DMT in Healthy Volunteers
- Conditions
- Pharmacokinetics; Safety; Tolerability
- Sites
- United States: Overland Park
- Lead sponsor
- Usona Institute
- Dates
- Start Dec 2022 · main results expected Sep 2023
NCT05698095 on ClinicalTrials.gov · record updated Nov 2023
Safety and Pharmacokinetics of GH002 in Healthy Volunteers
- Conditions
- Healthy Volunteers
- Sites
- Netherlands: Groningen
- Lead sponsor
- GH Research Ireland Limited
- Dates
- Start Dec 2022 · main results expected Nov 2023
NCT05753956 on ClinicalTrials.gov · record updated Jan 2024
SPL026 With or Without SSRIs in Participants With MDD
- Conditions
- Major Depressive Disorder
- Sites
- United Kingdom: Manchester, Liverpool
- Lead sponsor
- Small Pharma Ltd
- Dates
- Start Dec 2022 · main results expected Aug 2023
NCT05553691 on ClinicalTrials.gov · record updated Jun 2024
Acute Dose-dependent Effects of DMT in Healthy Subjects
- Conditions
- Healthy
- Sites
- Switzerland: Basel
- Lead sponsor
- University Hospital, Basel, Switzerland
- Dates
- Start Nov 2022 · main results expected Mar 2024
NCT05384678 on ClinicalTrials.gov · record updated Apr 2024
Ayahuasca and Esketamine for Major Depression
- Conditions
- Major Depression Severe
- Sites
- Brazil: Ribeirão Preto
- Lead sponsor
- University of Sao Paulo
- Dates
- Start Oct 2022 · main results expected Oct 2024
NCT07212946 on ClinicalTrials.gov · record updated Dec 2025
Clinical Study of DMT in Healthy Adults
- Conditions
- Healthy Volunteers
- Sites
- Brazil: Natal
- Lead sponsor
- Biomind Labs Inc.
- Dates
- Start Jun 2022 · main results expected Nov 2022
NCT05573568 on ClinicalTrials.gov · record updated Feb 2023
Single Ascending Dose Study With BPL-003 in Healthy Subjects
- Conditions
- Pharmacokinetics in Healthy Adults
- Sites
- United Kingdom: London
- Lead sponsor
- Beckley Psytech Limited
- Dates
- Start Feb 2022 · main results expected Jan 2024
NCT05347849 on ClinicalTrials.gov · record updated Mar 2024
Single Ascending Dose Study With 5-MeO-DMT in Healthy Subjects
- Conditions
- Pharmacokinetics in Healthy Adults
- Sites
- United Kingdom: London
- Lead sponsor
- Beckley Psytech Limited
- Dates
- Start Sep 2021 · main results expected Jul 2022
NCT05032833 on ClinicalTrials.gov · record updated Oct 2022
Pharmacokinetics of GH001 in Healthy Volunteers
- Conditions
- Healthy Volunteers
- Sites
- Netherlands: Groningen
- Lead sponsor
- GH Research Ireland Limited
- Dates
- Start Jun 2021 · main results expected Oct 2021
NCT05163691 on ClinicalTrials.gov · record updated Dec 2021
Effects of Dimethyltryptamine in Healthy Subjects
- Conditions
- Healthy
- Sites
- Switzerland: Basel
- Lead sponsor
- University Hospital, Basel, Switzerland
- Dates
- Start Jun 2021 · main results expected Aug 2022
NCT04353024 on ClinicalTrials.gov · record updated Oct 2022
SPL026 (DMT Fumarate) in Healthy Subjects and MDD Patients
- Conditions
- Major Depressive Disorder
- Sites
- United Kingdom: Liverpool, London
- Lead sponsor
- Small Pharma Ltd
- Dates
- Start Feb 2021 · main results expected Oct 2022
NCT04673383 on ClinicalTrials.gov · record updated Mar 2024
Neurodynamics of Prosocial Emotional Processing Following Serotonergic Stimulation With N,N-Dimethyltryptamine (DMT) and Harmine in Healthy Subjects
- Conditions
- Emotions; Mood; Cognitive Function 1, Social; Empathy
- Sites
- Switzerland: Zurich
- Lead sponsor
- Psychiatric University Hospital, Zurich
- Dates
- Start Dec 2020 · main results expected Jul 2021
NCT04716335 on ClinicalTrials.gov · record updated Oct 2022
Clinical Study of GH001 in Depression
- Conditions
- Treatment Resistant Depression; Major Depressive Disorder; Depression
- Sites
- Netherlands: Maastricht
- Lead sponsor
- GH Research Ireland Limited
- Dates
- Start Nov 2019 · main results expected Nov 2021
NCT04698603 on ClinicalTrials.gov · record updated Aug 2023
Safety of GH001 in Healthy Volunteers
- Conditions
- Healthy Volunteers
- Sites
- Netherlands: Maastricht
- Lead sponsor
- GH Research Ireland Limited
- Dates
- Start Mar 2019 · main results expected Oct 2019
NCT04640831 on ClinicalTrials.gov · record updated Aug 2023
Antidepressant Effects of Ayahuasca: a Randomized Placebo Controlled Trial in Treatment Resistant Depression
- Conditions
- Major Depression
- Sites
- Brazil: Natal
- Lead sponsor
- Universidade Federal do Rio Grande do Norte
- Dates
- Start Feb 2014 · main results expected Dec 2016
NCT02914769 on ClinicalTrials.gov · record updated Apr 2025
Trifecta Research Study
- Conditions
- PTSD - Post Traumatic Stress Disorder; Cognitive Dysfunction; Brain Trauma; Brain Injuries
- Sites
- United States: Baltimore
- Lead sponsor
- Johns Hopkins University
- Dates
- Start Sep 2025 · main results expected Dec 2026
NCT06810765 on ClinicalTrials.gov · record updated Aug 2025
Pharmacokinetics of GH001 Delivered Via a Proprietary Aerosol Delivery Device in Healthy Subjects
- Conditions
- Healthy Volunteers
- Sites
- United Kingdom: London
- Lead sponsor
- GH Research Ireland Limited
- Dates
- Start Aug 2024 · main results expected Mar 2026
NCT06511947 on ClinicalTrials.gov · record updated Oct 2026
Phase 2 Clinical Trial of GH001 in Bipolar II Disorder
- Conditions
- Bipolar II Disorder
- Sites
- Germany: Dresden, Frankfurt, Münster; Netherlands: Leiden, Maastricht; United Kingdom: London, Oxford
- Lead sponsor
- GH Research Ireland Limited
- Dates
- Start Apr 2023 · main results expected Nov 2024
NCT05839509 on ClinicalTrials.gov · record updated Feb 2025
Phase 2 Clinical Trial of GH001 in Postpartum Depression
- Conditions
- Postpartum Depression; Postnatal Depression
- Sites
- Netherlands: Amsterdam; United Kingdom: London, Sheffield
- Lead sponsor
- GH Research Ireland Limited
- Dates
- Start Mar 2023 · main results expected Aug 2024
NCT05804708 on ClinicalTrials.gov · record updated Feb 2025
Open-Label Dose-Ranging Study of Oral SM-001 in Healthy Adults
- Conditions
- Major Depression; Post Traumatic Stress Disorder
- Sites
- United States: Seattle
- Lead sponsor
- Advanced Integrative Medical Science Institute
- Dates
- Start Oct 2023 · main results expected Apr 2024
NCT05894902 on ClinicalTrials.gov · record updated Jul 2023
Ayahuasca Assisted Psychotherapy for Grief
- Conditions
- Bereavement
- Sites
- Spain: Barcelona
- Lead sponsor
- Beckley Med Foundation
- Dates
- Start Oct 2021 · main results expected Apr 2024
NCT06150859 on ClinicalTrials.gov · record updated Dec 2023
How to read this list.
- What’s included. A study appears when one of its registered drug interventions is N,N-DMT (dimethyltryptamine), ayahuasca or 5-MeO-DMT, a related but different molecule. Each card is tagged with its compound, and the compound filter separates them. A search for “DMT” also returns multiple sclerosis studies, where DMT stands for disease-modifying therapy, and dance/movement therapy studies; we check every result and leave those out.
- Status is the registry’s own: “Recruiting” means the study says it is enrolling participants now; “Not yet recruiting” has not started; “Under way” covers studies that are running but not enrolling, or enrolling by invitation only; “Stopped” covers studies that were suspended, ended early (terminated) or withdrawn before anyone took part.
- Phase describes the stage of drug research: phase 1 studies mostly look at safety and how the body handles a drug, often in healthy volunteers; phase 2 studies look for signs of an effect in people with a condition; phase 3 studies test it in larger groups. The registry’s glossary explains each phase.
- Registration is not a result. A record describes what a team planned to do. A completed study may not have published anything yet, and a record doesn’t say whether the compound helped. Results appear in journals, and sometimes on the record itself.
- Conditions are the terms each study registered. Our condition groups only sort them for the filter; the full terms are on each card.
- Studies register themselves and update their own records, so a status can be out of date. The “record updated” date on each card says when its team last changed it.
Keep reading.
- The DMT Library: science, history and evidence
- DMT therapy: what the clinical trials have tested, found and not yet shown
- DMT research today: who is studying DMT, how, and what they still don’t know
- 5-MeO-DMT vs DMT: two related molecules with very different research records
- Ayahuasca vs DMT: how the Amazonian brew differs from the molecule
We list what the registry lists; we don’t verify or endorse any study. This page is educational and is not medical advice. Studies that aren’t registered on ClinicalTrials.gov, including some registered only in national or regional registries, don’t appear here.